F-1/A: Baird Medical Files for Resale of 70.9% of Shares

Baird Medical Investment Holdings Limited filed an F-1/A registration statement for the potential resale of up to 34.4 million ordinary shares by selling securityholders and the issuance of 11.5 million shares upon warrant exercise.

Summary

• Baird Medical is a leading microwave ablation medical device developer and provider in the PRC, specializing in minimally invasive tumor treatments, particularly for thyroid nodules and breast lumps.
• The company ranked first in sales revenue and volume of microwave ablation needles for thyroid nodules and breast lumps in the PRC in 2022, and was the third largest overall microwave ablation medical device provider in the PRC in terms of sales revenue in 2022.
• Revenue increased by 17.7% from US$31.5 million in 2023 to US$37.0 million in 2024, driven by increased sales of MWA devices, particularly microwave therapeutic apparatuses.
• Net income increased from US$10.7 million in 2023 to US$12.6 million in 2024.
• Operating expenses increased by US$1.9 million from US$15.4 million in 2023 to US$17.3 million in 2024, primarily due to higher selling and marketing expenses and R&D expenditures.
• Cash used in operating activities significantly increased from US$1.0 million in 2023 to US$6.3 million in 2024, mainly due to increased R&D expenses and slower accounts receivable turnover.
• Accounts receivable turnover days increased from 337 days in 2023 to 411 days in 2024, indicating slower collection of payments.
• The company holds 54 registered patents and 28 pending patent applications in China as of December 31, 2024.
• The filing registers up to 11,500,000 ordinary shares issuable upon warrant exercise and up to 34,415,562 ordinary shares for resale by selling securityholders, representing approximately 70.9% of issued and outstanding shares as of August 6, 2025 (post-exercise basis).
• The closing price of ordinary shares on Nasdaq was US$2.05 on August 6, 2025, significantly below the warrant exercise price of US$11.50, making warrant exercise for cash unlikely.
• Certain selling securityholders acquired shares at prices substantially below current market prices (e.g., Sponsor Shares at US$0.004, Betters Medical shareholders at RMB1.4-RMB33.6), creating an incentive for them to sell even at current low prices.

Sentiment

Score: 3

Explanation: While the company shows revenue growth and R&D ambition, significant negative cash flow from operations, worsening accounts receivable, and the immense overhang of potential selling pressure from existing shareholders who acquired shares at much lower prices create substantial downside risk. Regulatory and geopolitical risks in China further compound the uncertainty.

Positives

• Increased revenue by 17.7% to US$37.0 million in 2024, primarily from MWA devices.
• Net income increased to US$12.6 million in 2024.
• Maintained a leading market position in microwave ablation for thyroid nodules and breast lumps in China.
• Expanded hospital network in China, with products procured by approximately 579 hospitals in 2024, up from 430 in 2022.
• Strong R&D capabilities with 54 registered patents and 28 pending applications, and a pipeline including AI-integrated robotic systems.
• Obtained U.S. FDA 510(k) clearance for disposable microwave ablation needle and system for soft tissue coagulation (excluding cardiac use) on November 13, 2023.

Negatives

• Cash used in operating activities significantly increased to US$6.3 million in 2024 from US$1.0 million in 2023.
• Accounts receivable turnover days increased from 337 days in 2023 to 411 days in 2024, indicating slower cash collection.
• Subsidy income decreased significantly from US$0.8 million in 2023 to US$266 in 2024.
• Incurred an administrative penalty of approximately RMB434,000 (US$651,657) in November 2024 for failing to renew a manufacture license in 2021, resulting in confiscation of approximately RMB4.2 million in sales revenue during the non-compliant period.
• High concentration of customers, with four largest customers accounting for 25.6%, 14.4%, 11.6%, and 10.2% of total revenue in 2024.
• Significant portion of outstanding shares (70.9%) are registered for potential resale by selling securityholders, many of whom have a substantial profit margin even at current low prices, creating potential downward pressure on the stock.

Risks

• Significant authority of the Chinese government to intervene or influence operations, including potential changes in economic, political, or social conditions and government policies.
• Uncertainties in the interpretation and enforcement of PRC laws, rules, and regulations, which can change quickly with little notice.
• Potential delisting from Nasdaq under the Holding Foreign Companies Accountable Act (HFCAA) if the PCAOB is unable to inspect auditors located in China for two consecutive years.
• Increased oversight by the Cyberspace Administration of China (CAC) over data security, particularly for companies seeking foreign listings, which could limit capital raising activities.
• Requirement for CSRC filing procedures for future offshore fund-raising activities, with potential for fines or hindrance if not complied with.
• Restrictions and limitations on the ability to transfer cash or assets out of mainland China or Hong Kong due to PRC government interventions and currency controls.
• Limited operating history and difficulty in predicting future prospects and performance, with historical high gross profit margins potentially unsustainable.
• Inability to obtain, maintain, or renew regulatory filings and registration certificates for medical devices in a timely manner, or at all.
• Failure to maintain or renew relationships with existing distributors and customers, or to maintain the sales network, especially given customer concentration.
• Sales may be adversely affected by the level of medical insurance reimbursement available to patients using products, and potential price reductions if products are covered by centralized national procurement.
• Inability to successfully complete product registration testing or clinical trials in a timely manner and at acceptable costs, or at all, for pipeline products.
• Failure to effectively manage deliverers or distributors, with potential for violations of agreements or laws by third parties.
• Inability to develop or successfully market new or commercially viable products and technologies, or to improve existing ones, in response to market changes.
• Quality defects in products leading to safety issues and potential product liability claims, as the company does not maintain product liability insurance.
• Inability to successfully market products to hospitals through tender processes, limiting sales network expansion.
• Potential requirements to contribute additional social insurance premiums or housing provident funds, or incur late payment fees or fines.
• Reliance on marketing service providers, with risks if relationships are not maintained or strategies are ineffective.
• Reliance on third parties for raw materials, with risks of supply disruption, quality issues, or cost increases.
• Dependence on information technology, with risks of system failures, security breaches, or data loss.
• Negative publicity and allegations affecting reputation, business, and financial condition.
• Inability to successfully implement business strategies or achieve anticipated returns.
• Geopolitical tensions between China and other countries affecting international expansion plans.
• Transactions with related parties presenting potential conflicts of interest.
• Potential fines for failure to comply with PRC laws and regulations relating to safety facilities.
• Disruptions to manufacturing facilities due to external factors or regulatory inspections.
• Inability to retain key management and personnel, or to attract and motivate qualified staff.
• Labor shortages or increases in labor costs.
• Intense competition in the medical technology industry, potentially affecting market share and profitability.
• Inaccurate projection of demand leading to inadequate supply or oversupply.
• Litigation, legal, or contractual disputes, governmental investigations, or administrative proceedings diverting management attention and incurring costs.
• Recently enacted and future legislation increasing difficulty and cost for regulatory approval and commercialization.
• Inadequate insurance coverage for potential liabilities.
• Requirement for significant capital to fund operations and future growth, which may not be available on acceptable terms.
• Discontinuation or reduction of preferential tax treatments or government incentives.
• Volatility in the price of securities due to various factors, including financial performance, regulatory changes, and sales by selling securityholders.
• The process of going public via SPAC business combination may result in less careful vetting of information compared to an IPO.
• Warrants increasing the number of shares eligible for future resale and resulting in dilution.
• Exclusive forum provision in warrant agreement potentially increasing costs for investors to bring claims.
• Warrants may never be 'in the money' and may expire worthless, especially given the current share price below exercise price.
• Ability to redeem unexpired public warrants prior to exercise at a disadvantageous time for holders.
• Increased costs and management time required as a public company.
• Potential characterization as a passive foreign investment company (PFIC) for U.S. federal income tax purposes, leading to adverse tax consequences for U.S. Holders.
• IRS may assert the company should be treated as a U.S. corporation for U.S. federal income tax purposes under Section 7874 of the Code.
• Uncertainties under PRC laws relating to procedures for U.S. regulators to investigate and collect evidence from companies in the PRC.
• Significant portion of outstanding shares subject to lock-up arrangements, which upon expiration, could lead to substantial sales and price decline.

Future Outlook

The company plans to broaden and deepen its product portfolio by registering Class III medical devices for breast lumps, pulmonary nodules, varicose veins, bone tumors, and uterine fibroids, with clinical trials and NMPA/CE certifications expected through 2027. It intends to enhance R&D capabilities by focusing on AI robotic surgery assistance for various tumor treatments, investing approximately US$18.7 million through 2027, and expanding its R&D team. International expansion into the U.S., EU, and Southeast Asia markets is planned, leveraging recent FDA clearance and pursuing CE Mark certification, with an investment of approximately US$1.7 million for clinical trials and applications. The company also aims to automate certain production steps to increase operational efficiency and product standardization.

Management Comments

• Management believes microwave ablation treatments are safer, less invasive, and easier to operate with faster recovery periods and lower complication rates for patients compared to traditional methods.
• Management believes microwave ablation treatments can help prevent cancer progression by curbing benign tumors from developing into malignant ones.
• Management believes patients diagnosed with benign tumors are inclined to seek tumor removal to avoid cancer progression risks.
• Management believes there are viable alternatives in the market that can meet demands and needs at comparable price points and quality for raw materials.
• Management believes the encouragement of innovation under the 2021 Medical Device Regulations is conducive to the development of innovative medical devices.
• Management believes the adjustment to review, approval, and filing procedures under the 2021 Medical Device Regulations are conducive to accelerating registration and marketing of pipeline products.
• Management believes the 2022 Supervisory and Administrative Measures for Production will not have a material impact on business operations due to existing licenses and compliance.
• Management believes the commissioned production was legal and valid under PRC laws and regulations.
• Management believes the Commission Guidelines will not have any material and adverse impact on business operation.
• Management believes the existing insurance coverage is in line with industry norms in the PRC and is sufficient for current operations.
• Management believes the offices and manufacturing plants currently leased are adequate to meet needs for the foreseeable future.
• Management believes employees contribute to rapid business growth and continued success depends on attracting, motivating, training, and retaining qualified employees.
• Management believes the company maintains a good working relationship with employees and has not experienced any major labor disputes.
• Management believes the company will have sufficient working capital to operate its business for the next 12 months from the date of issuance of the financial statement.
• Management believes the company is not exposed to unusual credit risks with financial institutions as they have high credit quality.

Industry Context

The company operates in the rapidly growing PRC microwave ablation market, which is the largest sector of China's tumor ablation therapy market, contributing 60% of the overall ablation market in 2021. The market size is projected to reach RMB12.26 billion by 2027 with a CAGR of 22.4%. The number of microwave ablation procedures in the PRC is expected to reach approximately 640,700 in 2027, representing a CAGR of 25.0% from 2022 to 2027, with most growth in thyroid nodule ablation. The U.S. and European microwave ablation markets are also projected to grow significantly, reaching US$151.5 million and US$110.2 million (thyroid cancer in Europe) by 2027, respectively. The U.S. market is concentrated, while Europe is fragmented. The industry is characterized by intense competition and rapid technological change, with new breakthroughs and treatments emerging frequently.

Comparison to Industry Standards

• The company ranked first among microwave ablation medical device providers in the treatment of thyroid nodules and breast lumps in the PRC in terms of sales revenue and sales volume of microwave ablation needles in 2022, according to the Frost & Sullivan Report.
• The company was the third largest microwave ablation medical device provider in the PRC in terms of sales revenue in 2022, with a market share of 19.0%, in a highly concentrated market where the top four manufacturers accounted for about 88.4% of sales.
• The company is the first to have proprietary microwave ablation medical devices specifically approved for the treatment of thyroid nodules successfully registered as Class III medical devices in the PRC, providing a first-mover advantage over competitors like ECO Medical, Vison Medical, and Canyon Medical, who have Class III certificates for liver cancer but not thyroid nodules or other planned indications.
• The company's accounts receivable turnover days of 411 days in 2024 (up from 337 days in 2023) are significantly higher than typical industry standards, indicating a slower collection period for customer payments.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not a party to, nor aware of, any legal proceeding, investigation, or claim likely to have a material adverse effect on its business, financial condition, or results of operations.
• The company may from time to time be subject to various legal or administrative claims and proceedings arising in the ordinary course of business.

Related Party Transactions

• In 2023, Betters Medical and Haimei Wu (Chairwoman and CEO) repurchased preference shares from one Electing Preference Shares Holder for RMB10,000,000 and US$683,638.21 (Betters Medical) and US$499,994.24 (Haimei Wu).
• On June 30, 2023, Grand Fortune Capital (H.K.) Company Limited, an affiliate of GFC, purchased 641,371 preference shares from an Electing Preference Shares Holder for US$8,712,178.41.
• The repurchase request of a third Electing Preference Shares Holder for 174,825 Preference Shares (valued at RMB17.8 million as of September 30, 2023) remains outstanding.
• Haimei Wu is the legal owner of premises co-occupied by the Guangdong branch office of Baide Suzhou.
• The company's use of its Taicang Plant is under a sublease agreement with affiliated entities.
• The company is party to a Subscription Agreement dated June 30, 2021, and a Shareholders Agreement dated July 5, 2021, with Betters Medical, Baide Medical Investment Company Limited, Haimei Wu, and other subsidiaries/investors.
• The Sponsor Support Agreement (June 26, 2023) outlines vesting and forfeiture conditions for 1,350,000 Sponsor Earnout Shares based on stock price or change of control.
• The Betters Medical Shareholder Support Agreement (June 26, 2023) includes voting agreements, transfer restrictions, and waiver of dissenters' rights for key Betters Medical shareholders.
• A Subscription Agreement with GFC (September 30, 2024) resulted in the issuance of 290,000 Series A convertible preferred shares for US$2.9 million.
• A Subscription Agreement with Wu Wenyuan (September 30, 2024) for US$2 million for 200,000 Series A Preferred Shares has not yet consummated.
• The Lock-Up Agreement (October 1, 2024) restricts transfer of Ordinary Shares acquired by Betters Medical for six months or until a change of control, and outlines vesting conditions for 8,823,529 Betters Medical Earnout Shares.
• The Warrant Assignment, Assumption and Amendment Agreement (October 1, 2024) converted ExcelFin Public Warrants into Baird Medical Warrants and cancelled ExcelFin Private Placement Warrants.
• The Registration Rights Agreement (October 1, 2024) grants demand and piggyback registration rights to certain holders of Registrable Securities.
• In January 2025, 50,000 Ordinary Shares were issued to J.V.B. Financial Group, LLC (Cohen) pursuant to an engagement letter.
• In January 2025, 583,529 Ordinary Shares were issued to Grand Fortune Capital (H.K.) Company Limited due to a valuation shortfall.

Stakeholder Impact

• **Shareholders**: Potential significant dilution and downward pressure on share price due to the large number of shares registered for resale by selling securityholders who acquired them at much lower prices. U.S. shareholders face risks related to PRC government intervention, delisting under HFCAA, and potential adverse U.S. tax consequences if the company is deemed a PFIC or U.S. corporation.
• **Employees**: Continued focus on attracting, motivating, training, and retaining qualified employees, with competitive compensation packages and a new equity incentive plan. However, labor shortages or increased labor costs could impact the company.
• **Customers (Hospitals)**: Continued access to microwave ablation medical devices and pipeline products. Potential impact from changes in medical insurance reimbursement policies or centralized procurement, which could affect product pricing and demand.
• **Suppliers**: Continued reliance on third-party suppliers for raw materials, with risks of supply disruption or quality issues affecting production.
• **Creditors**: The company's ability to service debt depends on dividends from PRC subsidiaries, which are subject to PRC laws and regulations on retained earnings and statutory reserves. Increased debt levels and negative operating cash flow could impact creditworthiness.

Next Steps

• Complete clinical trials for breast lumps (expected by June 2026).
• Complete clinical trials for pulmonary nodules (expected by June 2026).
• Complete NMPA registration procedures and obtain applicable registration certificates for breast lumps and pulmonary nodules (expected by December 2026).
• Submit EU CE certification materials for thyroid nodule products (expected December 2025) and obtain certification (expected mid-2026).
• Submit clinical trial results for NMPA and CE certification for breast lumps and pulmonary nodules (around August 2026).
• Obtain EU CE certification for breast lump products (expected between December 2026 and mid-2027).
• Commence product registration testing for bone tumors and uterine fibroids in PRC (expected to be completed by June 2027).
• Conduct pre-clinical activities on microwave ablation intelligence (AI robotic surgery assistance) in 2025 and complete relevant clinical trials in 2027.
• Expand and increase headcount of the R&D team.
• Establish overseas offices and seek collaboration with local sales channels in the U.S., EU, and Southeast Asia.
• Automate certain production steps in manufacturing plants.

Key Dates

Recommendation

Despite revenue growth and profitability, the company exhibits severe red flags for investors. The substantial negative cash flow from operations (US$6.3 million in 2024) and a significant increase in accounts receivable turnover days (411 days) indicate a deteriorating cash conversion cycle and potential liquidity issues. The registration for resale of 70.9% of outstanding shares by selling securityholders, many of whom acquired their shares at prices orders of magnitude lower than the current market price (e.g., US$0.004 for Sponsor Shares vs. US$2.05 current), creates an overwhelming overhang that is highly likely to drive the share price significantly lower. This massive potential selling pressure, combined with the unlikelihood of warrant exercise (exercise price US$11.50 vs. current US$2.05), means public shareholders bear the full brunt of dilution and selling. Furthermore, the company faces substantial and evolving regulatory, geopolitical, and data security risks associated with operating primarily in China, including potential delisting under the HFCAA. The administrative penalty for past non-compliance highlights operational risks. For a seasoned investor, the combination of deteriorating cash flow, extreme selling pressure from insiders, and high regulatory/geopolitical uncertainty makes this a 'strong sell' as the downside risk appears far to outweigh any potential upside.

Keywords

Microwave Ablation, Medical Devices, Thyroid Nodules, Liver Cancer, Breast Lumps, China Healthcare, SEC Filing, F-1/A, Public Offering, Warrants, Selling Securityholders, Corporate Governance, Risk Factors, Financial Performance, R&D, AI Robotic Surgery, International Expansion, PRC Regulations, HFCAA, PCAOB, Nasdaq Listing, Capital Raise, Dilution